Tillotts Pharma Ag

University College London

Tillotts Pharm Ag

Esther Maria Furrer

Tea Gunde

Sebastian Meyer

Inger Sandlie

Abdul Waseh Basit

Roberto Carlos Bravo González

Jan Terje Andersen

Felipe José Oliveira Varum

Roberto Carlos Bravo Gonzaléz

Stian Foss

Vipul Yadav

Terje Jan Andersen

The present invention relates to antibodies which bind to TNFα and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.

Antibody variants

The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNFα), to processes for their production, and to their therapeutic uses.

Anti-TNF-alpha-antibodies and functional fragments thereof

The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF&#x3b1;), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Topical treatment of inflammatory bowel disease using antibodies and fragments thereof

The present invention relates to antibodies which bind to TNF&#x3b1; and comprise a modified Fc region. The antibodies of the invention have improved resistance against proteolytic degradation and good effector functions and/or pharmacokinetic properties.

The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF&#x3b1;), to processes for their production, and to their therapeutic uses.

Growing community of inventors

Rheinfelden, Switzerland

Esther Maria Furrer